



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/164,223	09/30/1998	ALEXANDER GAIGER	210121	6400
500	7590	03/30/2004	EXAMINER	
SEED INTELLECTUAL PROPERTY LAW GROUP PLLC 701 FIFTH AVE SUITE 6300 SEATTLE, WA 98104-7092				SCHWADRON, RONALD B
ART UNIT		PAPER NUMBER		
		1644		

DATE MAILED: 03/30/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	09/164,223	GAIGER ET AL.	
	Examiner	Art Unit	
	Ron Schwadron, Ph.D.	1644	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on _____.
- 2a) This action is **FINAL**. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 104 and 107-112 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) 104 and 107 is/are allowed.
- 6) Claim(s) 108-112 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) Notice of References Cited (PTO-892)
- 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
 Paper No(s)/Mail Date _____.
- 4) Interview Summary (PTO-413)
 Paper No(s)/Mail Date _____.
- 5) Notice of Informal Patent Application (PTO-152)
- 6) Other: _____.

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 1/16/2004 has been entered.
2. Claims 104,107-112 are under consideration.
3. The rejection of claims 104,105,110-112 under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention for the reasons elaborated in paragraph 3 of the Office Action mailed 4/16/2003 is withdrawn in view of the amended claims and the cancellation of claim 105.
4. The rejection of claim 107 under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention for the reasons elaborated in paragraph 5 of the Office Action mailed 4/16/2003 is withdrawn in view of the amended claim.
5. The rejection of claims 105,109,111,112 under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention for the reasons elaborated in paragraph 7 of the Office Action mailed 4/16/2003 is withdrawn in view of the amended claims and cancellation of claim 105.
6. The rejection of claim 107 under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention for the reasons

elaborated in paragraph 4 of the Office Action mailed 4/16/2003 is withdrawn in view of the amended claim.

7. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

8. Claims 108-112 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

There is no support in the specification as originally filed for the recitation of "composition" in claims 108-112. While the specification discloses vaccines with the ingredients recited in claims 108-112 (eg. non-specific immune response enhancer), there is no disclosure of non-vaccine compositions in the specification as originally filed which contain a non-specific immune response enhancer. These two terms differ in scope in that the art recognizes that a vaccine is used for treatment of disease, including human disease, while the term composition does not necessarily imply that the composition would be used to treat human disease. There is no support in the specification as originally filed for the scope of the claimed invention (eg. the claimed invention constitutes new matter).

Regarding applicants comments about the specification, page 9, the quoted passage of the specification discloses a composition containing WT1 polypeptides. It does not disclose a composition containing a WT1 polypeptide and a non-specific immune response enhancer. Regarding the specification, page 28, the quoted passage discloses vaccines containing a WT1 polypeptide and a non-specific immune response enhancer. While said passage discloses vaccines with the ingredients recited in claims 108-112 (eg. non-specific immune response enhancer), there is no disclosure of non-vaccine compositions in the specification as originally filed which contain a non-specific immune response enhancer. These two terms differ in scope in that the art recognizes

that a vaccine is used for treatment of disease, including human disease, while the term composition does not necessarily imply that the composition would be used to treat human disease. Applicant appears to be arguing that the instant limitations are obvious in view of the aforementioned passages of the specification. However, obviousness is not the appropriate standard with regards to issues of written description. The CAFC stated in Lockwood v. American Airlines Inc., 41 USPQ2d 1961 (Fed. Cir. 1997) that:

3. *Patentability/Validity -- Specification -- Written description (§ 115.1103)*

Patent's entitlement to earlier filing date extends only to that which is disclosed in prior application, and does not extend to subject matter which is not disclosed, but would be obvious over what is expressly disclosed; one shows that one is "in possession" of invention of patent by describing invention, with all its claimed limitations, not that which makes it obvious, and although prior application need not describe claimed subject matter in exactly same terms used in claims, prior specification must contain equivalent description of claimed subject matter, and description which renders obvious invention for which earlier filing date is sought is not sufficient.

The CAFC also stated in Lockwood v. American Airlines Inc., 41 USPQ2d 1961 (Fed. Cir.

1977) that:

The invention is, for purposes of the 'written description' inquiry, whatever is now claimed .") (emphasis in original). One does that by such descriptive means as words, structures, figures, diagrams, formulas, etc., that fully set forth the claimed invention. Although the exact terms need not be used in haec verba , see Eiselstein v. Frank , 52 F.3d 1035, 1038, 34 USPQ2d 1467, 1470 (Fed. Cir. 1995) ("[T]he prior application need not describe the claimed subject matter in exactly the same terms as used in the claims.. . ."), the specification must contain an equivalent description of the claimed subject matter. A description which renders obvious the invention for which an earlier filing date is sought is not sufficient.

9. Claims 104 and 107 are allowed.

10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ron Schwadron, Ph.D. whose telephone number is 571

272-0851. The examiner can normally be reached Monday to Thursday from 7:30am to 6:00 pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan, can be reached at 571 272 0841. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



RONALD B. SCHWADRON
PRIMARY EXAMINER
GROUP 1800 1602

Ron Schwadron, Ph.D.
Primary Examiner
Art Unit 1644